Still Detox provides 24/7 medically supervised barbiturate addiction treatment and detox for adults in Boca Raton, Florida. Our board-certified Medical Director manages barbiturate withdrawal using phenobarbital stabilization and individualized taper protocols in a private, 14-bed setting adjacent to Boca Regional Hospital. Barbiturate withdrawal is among the most medically dangerous of all drug withdrawals — call now for a confidential, same-day assessment.
Free & confidential — takes about 60 seconds
Joint Commission Accredited
Florida DCF Licensed
LegitScript Certified
Verified by Psychology TodayBarbiturate addiction is classified by the DSM-5 as sedative, hypnotic, and anxiolytic use disorder — a chronic condition defined by compulsive barbiturate use despite significant harm to health, relationships, or daily functioning. Barbiturates are a class of central nervous system depressants that enhance the activity of GABA, the brain's primary inhibitory neurotransmitter, by binding directly to the GABA-A receptor chloride channel. This direct binding produces a more pronounced and less selective CNS depression than benzodiazepines — giving barbiturates a narrower therapeutic window and higher overdose lethality.
Barbiturates were once widely prescribed for anxiety, insomnia, and seizure disorders. Their high addiction liability and lethal overdose risk drove a clinical shift toward benzodiazepines beginning in the 1970s. Today, barbiturates in clinical use include phenobarbital (Luminal) for epilepsy, butalbital (Fioricet, Fiorinal) for tension headaches, and pentobarbital (Nembutal) for procedural sedation. Dependence develops rapidly — sometimes within weeks — and barbiturate withdrawal carries a higher mortality risk than benzodiazepine withdrawal when unsupported.
Barbiturates act directly on the GABA-A receptor chloride channel, producing CNS depression that is dose-dependent and lacks the ceiling effect that makes benzodiazepines comparatively safer. With chronic use, the brain's GABA receptor system downregulates to compensate — and when barbiturates are removed, the nervous system rebounds into a state of severe excitability that can produce grand mal seizures, delirium, hyperthermia, and cardiovascular collapse.
Barbiturate withdrawal is widely regarded as the most medically dangerous withdrawal syndrome of any substance class. The high addiction liability and lethal withdrawal risk of barbiturates is precisely why benzodiazepines replaced them as the clinical standard for anxiety and insomnia treatment. An unmanaged barbiturate withdrawal can be fatal. Unlike alcohol withdrawal, there is no widely available home monitoring protocol — barbiturate discontinuation must occur under physician supervision with stabilization using a long-acting barbiturate taper.
At Still Detox, barbiturate detox is managed using phenobarbital stabilization: an individualized stabilizing dose of phenobarbital is established based on the client's specific drug, dose, and duration of use, then tapered incrementally under daily physician oversight. Vital signs are monitored around the clock. Emergency services are immediately accessible through our adjacent Boca Regional Hospital campus.
Barbiturate withdrawal demands clinical precision, physician-level oversight, and immediate access to emergency services. Still Detox is built for exactly this level of medical complexity.
Our Medical Director, board-certified in addiction medicine, evaluates every client within 24 hours of admission and establishes the phenobarbital stabilization and taper protocol. Daily physician assessment drives taper adjustments throughout the withdrawal period.
Located on the University Hospital campus, adjacent to Boca Regional Hospital. Emergency cardiovascular and neurological services are immediately available — a critical safeguard for the most medically dangerous withdrawal syndrome in addiction medicine.
Private rooms available with around-the-clock nursing monitoring, professional catering, and individualized comfort care throughout acute barbiturate withdrawal — managed without the chaos of a hospital ward.
Barbiturate detox flows directly into inpatient residential treatment on the same campus. The anxiety, seizure disorder, or chronic pain condition that drove barbiturate use is addressed in the therapeutic program that follows detox.
Every team member, from behavioral health techs through the Medical Director, is fluent in English and Spanish. Complete barbiturate addiction treatment services are available in Spanish.
Unlike most facilities, Still Detox fully accommodates legitimate service animals during barbiturate addiction treatment. Dogs and cats are welcome. Recovery should never require leaving your companion behind.
People come to Still Detox at their most vulnerable. Here is what they say about the clinical care, the staff, and the recovery they found on the other side.
Barbiturate withdrawal timeline differs significantly based on the specific drug's half-life. Short-acting barbiturates such as secobarbital (Seconal) and pentobarbital (Nembutal) produce rapid withdrawal onset. Long-acting barbiturates such as phenobarbital (Luminal) produce a more gradual, extended withdrawal course. Butalbital — found in headache medications such as Fioricet and Fiorinal — occupies an intermediate position. Understanding which barbiturate a client is physically dependent on determines both the stabilization strategy and the expected withdrawal timeline.
All barbiturate withdrawal syndromes share a common mechanism: rebound CNS hyperexcitability as GABA-A receptor suppression is removed. Seizure risk is present across all barbiturate classes and is the primary clinical justification for inpatient physician-managed detox rather than outpatient or home-based withdrawal management.
Withdrawal from short-acting barbiturates begins 8 to 15 hours after the last dose. Early symptoms include anxiety, restlessness, insomnia, tremors, nausea, vomiting, abdominal cramps, elevated heart rate, and elevated blood pressure. At Still Detox, phenobarbital stabilization begins immediately upon admission to prevent the withdrawal from progressing to its dangerous peak.
The highest-risk window for barbiturate withdrawal. Grand mal seizures, delirium, hallucinations, and hyperthermia can occur in individuals with significant physical dependence. This window carries the highest mortality risk of any drug withdrawal syndrome when unmanaged. Physician monitoring, phenobarbital taper, and access to emergency intervention are all required during this phase.
Acute physical symptoms begin to resolve as the phenobarbital taper progresses. Anxiety, insomnia, emotional instability, and cognitive difficulty persist. Sleep disturbances and sensory hypersensitivity are common. The taper schedule is adjusted based on daily clinical assessment as the client transitions toward stability. Phenobarbital taper for long-acting barbiturate dependence may extend beyond this window.
Post-acute withdrawal syndrome from barbiturate dependence can persist for weeks to months, particularly after long-term high-dose use. Symptoms include chronic anxiety, insomnia, cognitive impairment, mood instability, and sensory hypersensitivity. PAWS is a significant driver of relapse without the residential therapeutic program that addresses the underlying condition driving barbiturate use.
Barbiturate withdrawal has the narrowest clinical margin of any substance. Knowing exactly what to expect removes one of the biggest barriers to making the call. Here is how barbiturate addiction treatment at Still Detox works from first contact through residential care.
Your admissions representative gathers your barbiturate use history, specific drug, current dose, duration of use, and co-occurring medical conditions. Out-of-network PPO benefits are verified. Travel and logistics are coordinated before your arrival.
A pre-admission call within three days of your arrival covers your full barbiturate history, any co-occurring seizure disorder, anxiety condition, or chronic pain condition, and current medications — so the clinical team has a complete picture on day one.
A nurse and behavioral health tech meet you together for a structured intake. Phenobarbital stabilization begins promptly on admission to prevent withdrawal from progressing to its dangerous peak. Baseline vitals and urine toxicology screen are completed during the first hours.
Within 24 hours, the Medical Director completes a full history and physical and establishes your individualized phenobarbital taper protocol. The stabilizing dose and taper schedule are calibrated to your specific barbiturate, dose, duration of use, and medical history.
Vital signs monitored around the clock throughout the acute withdrawal window. Daily physician assessment drives taper adjustments. Comfort medications address anxiety, insomnia, nausea, and elevated blood pressure. Typical stay is 7 to 14 days, longer for high-dose long-duration dependence.
Once clinical stability is established, you step directly into residential treatment on the same campus. The condition that drove barbiturate use — epilepsy management, anxiety, chronic headaches — is addressed therapeutically without returning to barbiturates as the clinical solution.
The DSM-5 classifies barbiturate addiction as sedative, hypnotic, and anxiolytic use disorder, using 11 diagnostic criteria that apply across the entire CNS depressant class. A diagnosis requires 2 or more criteria in a 12-month period. Mild is 2 to 3; moderate is 4 to 5; severe is 6 or more. Physical dependence — the GABA system's adaptation to chronic barbiturate exposure — can exist even without a formal use disorder diagnosis.
Taking barbiturates in larger amounts or more frequently than prescribed or intended. Common in individuals using butalbital for chronic headaches who find the prescribed dose no longer provides relief, leading to incremental escalation that crosses into physical dependence.
A persistent desire to reduce or stop barbiturate use combined with repeated unsuccessful efforts. The emergence of withdrawal symptoms within hours of missing a dose makes self-discontinuation feel neurologically impossible — and genuinely dangerous without clinical management.
Spending significant time obtaining, using, or recovering from barbiturates. This includes doctor shopping for prescriptions, filling scripts early, or organizing daily activities around dosing schedules to prevent withdrawal onset.
A strong urge to use barbiturates, typically driven by the onset of withdrawal symptoms rather than pursuit of euphoria. In barbiturate dependence, craving is often the nervous system's signal that GABA receptor function is destabilizing — a physiological warning, not a behavioral choice.
Barbiturate use that interferes with work performance, family responsibilities, or academic obligations. Sedation, cognitive blunting, and impaired coordination associated with regular barbiturate use progressively erode functional capacity.
Persisting with barbiturate use despite conflict with family or partners caused or worsened by the drug. Behavioral changes including excessive sedation, memory impairment, irritability, and emotional withdrawal are common relationship stressors in barbiturate dependence.
Giving up hobbies, social engagement, or valued activities in order to use barbiturates or to avoid situations where a dose might be missed and withdrawal triggered. Social withdrawal narrows progressively as the disorder deepens.
Using barbiturates while driving, operating machinery, or combining them with alcohol, opioids, or benzodiazepines. The combination of barbiturates with other CNS depressants is particularly dangerous due to synergistic respiratory depression — a leading cause of barbiturate overdose death.
Persisting with barbiturate use despite awareness of physical or psychological harm including cognitive impairment, increased fall risk, respiratory depression, liver toxicity, and overdose risk. The narrow therapeutic window of barbiturates means the line between therapeutic dose and lethal dose is clinically thin.
Requiring significantly higher barbiturate doses to achieve the same sedative, anxiolytic, or analgesic effect, or finding that the prescribed dose no longer produces its intended effect. Tolerance develops rapidly with barbiturates — faster than with benzodiazepines — and drives dose escalation that compounds overdose risk.
Experiencing anxiety, restlessness, tremors, insomnia, nausea, elevated heart rate, or seizures when barbiturates are delayed or stopped. The presence of withdrawal symptoms within 8 to 24 hours of the last dose is the most clinically urgent indicator that medically supervised detox is required before any attempt at discontinuation.
Source: DSM-5 sedative, hypnotic, and anxiolytic use disorder criteria. If any 2 or more of these apply in a 12-month period, a clinical diagnosis is appropriate. Do not attempt barbiturate discontinuation without speaking to a physician first.
Talk to Admissions ConfidentiallyThese are real before-and-after moments from people who completed treatment at Still Detox and built lasting sobriety. Each one reflects more than a physical change — it is a life no longer organized around a substance the nervous system had come to depend on for basic stability.
Barbiturate withdrawal can produce grand mal seizures in individuals with physical dependence, with onset within 8 to 72 hours of the last dose depending on the specific barbiturate. Unlike alcohol withdrawal seizures, barbiturate seizures can occur with little preceding warning and can be refractory to standard seizure management without the right medications available. There is no reliable self-assessment tool for predicting individual seizure risk.
Barbiturates have a narrower margin between a therapeutic dose and a lethal dose than virtually any other commonly misused substance. Someone attempting to self-manage withdrawal by adjusting their own dose faces a genuine overdose risk — the same pharmacological property that made barbiturates clinically dangerous as a prescription class makes self-tapering without physician guidance acutely hazardous.
Many clients using barbiturates have an underlying seizure disorder, anxiety condition, or chronic pain syndrome that the drug was originally managing. Stopping barbiturates without a clinical plan for those conditions means both the withdrawal risk and the untreated underlying condition must be managed simultaneously — a level of complexity that requires inpatient physician care, not home management.
Still Detox is an out-of-network provider for most insurance plans. Many clients with PPO plans that carry out-of-network benefits apply that coverage toward barbiturate detox and residential care. Our admissions team verifies your specific benefits at no cost and with no obligation before admission — so you have complete financial clarity before committing.
We confirm what your plan covers, walk through any out-of-pocket responsibility, and explain flexible payment options including monthly payment plans and promissory arrangements. Financial concerns should never delay someone from seeking medically necessary barbiturate detox.
Don't see your plan? Call us. Our specialists work with many coverage scenarios and will give you an honest answer before you make any commitment.
Barbiturate withdrawal demands clinical precision in a setting that is calm enough to allow the nervous system to stabilize. Still Detox pairs hospital-adjacent medical infrastructure with an environment designed for recovery, not crisis management alone.
Phenobarbital is a first-line medication for epilepsy. Many clients with barbiturate dependence have a genuine seizure disorder that required barbiturate treatment. Still Detox manages the detox and coordinates alternative seizure management with the client's neurologist — discontinuation does not mean abandoning epilepsy treatment.
Butalbital-containing medications such as Fioricet and Fiorinal are commonly prescribed for tension and migraine headaches. Physical dependence develops more readily than many prescribers and patients recognize. Still Detox manages butalbital withdrawal and works with clients to identify non-barbiturate headache management strategies during residential care.
Barbiturates are frequently combined with alcohol, benzodiazepines, or opioids — combinations that dramatically increase overdose risk and complicate withdrawal management. Still Detox has the clinical infrastructure to manage multiple simultaneous CNS depressant withdrawals under physician supervision.
Barbiturate withdrawal is the most medically dangerous withdrawal in addiction medicine. It requires immediate physician supervision, phenobarbital stabilization, and an inpatient clinical environment adjacent to emergency services. Our team is on-site 24 hours a day, same-day assessments are available now, and residential care follows directly. Call now — this is not a situation to manage alone.
We're here 24/7. Speak with admissions, confidentially and with no obligation.
☎ Call (561) 556-2677Accreditations & Memberships
We understand that there are no shortcuts on the path to recovery, and our compassionate team offers unwavering support and intensive care throughout your healing journey.
Still Detox is a member of Still Behavioral Health Group.
Get Help Now
If you or someone you care about is seeking support for substance abuse and addiction challenges, we are here to offer our assistance. This is where your journey towards healing begins.
© 2026 | Still Detox Drug and Alcohol Treatment Center in Florida
950 NW 9th CT, Boca Raton, FL 33486
